WISE announced the closing of an oversubscribed €30 million Series D financing round. The round was joined by ENEA Tech and Biomedical, an Italian foundation focused on innovation and technology transfer in the biomedical sector. ENEA Tech and Biomedical is joining WISE’s investor base as a strategic partner.
The final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank supported by InvestEU. The round also included an equity investment from Wallaby, the family office of the Scagliarini family, along with existing financial partners New Frontier, Eureka Venture SGR, and Indaco Ventures SGR.
WISE is a medical device company focused on advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface applications.
The company plans to use the proceeds primarily to advance the development and clinical adoption of its Heron lead, a spinal cord stimulation product designed to treat chronic pain.
The Heron lead is designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique. WISE said the product combines the therapeutic precision of surgical paddle leads with the lower procedural burden of cylindrical leads.
The company said this approach can support higher energy efficiency, improved anatomical coverage, better neural signal sensing, and reduced lead migration.
The funding will support the Heron lead’s regulatory certification pathway and first-in-human study. It will also help WISE scale commercialization of its broader electrode portfolio across target markets.
WISE’s proprietary Supersonic Technology enables the production of implantable electrodes and brain-computer interface systems made from stretchable electronic circuits integrated into ultra-thin elastomeric foils. Compared to conventional rigid electrodes, the company said its devices provide better tissue conformability, softness, and adhesion.
Along with the Heron lead, the round will support expanded commercialization of the WISE Cortical Strip, a soft and stretchable electrode for intraoperative neurophysiological monitoring during brain tumor and epilepsy surgeries. The WISE Cortical Strip has CE mark under MDR, FDA clearance, and is commercially available in Europe, the U.S., and Australia.
The financing round also brings governance changes, including the appointment of Laura Iris Ferro as Chairperson of WISE and the addition of Giuseppe Corvino to the Board of Directors.
KEY QUOTES:
“The oversubscription of this Series D round is a testament to the strength of what our team has built — in technology, in medical research, and in our relationships with clinicians and partners. Welcoming ENEA Tech and Biomedical into our investor base strengthens our mission to bring genuinely transformative neurotechnology to patients worldwide. With the Heron lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need. This financing gives us the resources to complete the journey from bench to bedside.”
Luca Ravagnan, Chief Executive Officer of WISE
“WISE represents a compelling convergence of advanced materials science, neuroscience, and clinical innovation. Welcoming ENEA Tech and Biomedical on board is a testament to the strength of what WISE has built. I am proud to help the company scale its technology and bring high-impact solutions to patients with neurological conditions and chronic pain.”
Laura Iris Ferro, Chairperson of WISE
